****

**General CME Information**

**Accreditation:**

Global Learning Collaborative (GLC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:**

Global Learning Collaborative designates this live activity for a maximum of 6.25 *AMA PRA Category 1 CreditsTM.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure of Conflicts of Interest:**

In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

**Faculty:**

|  |  |
| --- | --- |
| ***Name of Faculty*** | ***Reported Areas of Conflict*** |
| Stephen M. Cohen, MD, FACOG | **Consulting Fees:** AbbVie, CooperSurgical |
| Sheryl A. Kingsberg, PhD | **Consulting Fees:** AMAG Pharmaceuticals, Dare, Emotional Brain, Endoceutics, IVEX, Lupin Pharmaceuticals, Inc., Sprout, Strategic Science Technologies, Therapeutics MD  **Commercial Interest Speakers Bureau:** AMAG Pharmaceuticals, Therapeutics MD Contracted Research: AMAG Pharmaceuticals, Dare, Endoceutics, Palatin **Ownership Interest:** Viveve |
| Erin D. Michos, MD, MHS, FACC, FAHA, FASE | No relationship reported |
| Michael Miller, MD, FACC, FAHA | **Consulting Fees:** Amarin |
| David J. Portman, MD | **Grant/Research Support:** Boehringer Ingelheim, Endoceutics, Palatin Technologies, QuatRx Pharmaceuticals, Shionogi Pharmaceuticals, TherapeuticsMD  **Consultant/Advisory Board:** AMAG Pharmaceuticals, Agile Therapeutics, Duchesnay Pharmaceuticals, ITF Pharma  **Commercial Interest Speakers Bureau:** AMAG Pharmaceuticals  **Salary and Stockholder:** Sermonix Pharmaceuticals |
| Donna Ryan, MD | **Consulting Fees:** Alyvent, Amgen, Bausch Health, Boeringer Ingelheim, Epitomee, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, Scientific Intake  **Commercial Interest Speakers Burea:** Novo Nordisk  **Contracted Research:** SELECT Steering Committee (Novo Nordisk)  **Ownership Interest:** Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health, Scientific Intake |
| Jane R. Schwebke, MD | **Consulting Fees:** Hologic, Talis  **Contracted Research:** BD Diagnostics, Hologic, Lupin, Mycovia Pharmaceuticals, Synexis  **Ownership Interest:** Talis |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
| Lee Philip Shulman, MD, FACOG, FACMG | **Consulting Fees:** Allergan, Biogix, Celula China, Cooper Surgical, Lupin Pharmaceuticals, Inc., Natera, Vermillion/Aspira **Commercial Interest Speakers Bureau:** AMAG Pharmaceuticals, Lupin Pharmaceuticals, Inc., Myriad, Vermillion/Aspira |
| Andrea J. Singer, MD, FACP, CCD | **Consulting Fees:** AgNovos, Amgen, Eli Lilly, Radius, UCB  **Commercial Interest Speaker Bureau:** Amgen, Radius, TherapeuticsMD  **Contracted Research:** Radius Health, UCB |

**Reviewers/Planners/Authors:**

|  |  |
| --- | --- |
| ***Name of Reviewer/Planner/Author*** | ***Reported Areas of Conflict*** |
| Sean T. Barrett | No relationship reported |
| Eliot Brinton, MD, FAHA, FNLA | **Consulting Fees:** Amarin, Esperion, Kowa  **Commercial Interest Speakers Bureau:** Amarin, Amgen, Boehringer, Kowa, Merck, Nova, Regeneron, Sanofi |
| Kenneth Brown | No relationship reported |
| Ben Caref, PhD | No relationship reported |
| Stephen Chavez | No relationship reported |
| Stephen M. Cohen, MD, FACOG | **Consulting Fees:** AbbVie, CooperSurgical |
| Barry A. Fiedel, PhD | No relationship reported |
| William M. Geisler, MD, MPH | **Consulting Fees:** Hologic, Inc., Roche |
| Sue Grossman | No relationship reported |
| Amanda Hilferty | No relationship reported |
| Sheryl A. Kingsberg, PhD | **Consulting Fees:** AMAG Pharmaceuticals, Dare, Emotional Brain, Endoceutics, Lupin Pharmaceuticals, Inc., Sprout, Strategic Science Technologies, Therapeutics MD, IVEX **Commercial Interest Speakers Bureau:** AMAG Pharmaceuticals, Therapeutics MD **Contracted Research:** AMAG Pharmaceuticals, Dare, Endoceutics, Palatin **Ownership Interest:** Viveve |
| Jessica McGrory | No relationship reported |
| William Mencia, MD, FACEHP, CHCP | No relationship reported |
| Margo B. Minnissian, PhD, ACNP | **Consulting Fees:** Amgen |
| David J. Portman, MD | **Grant/Research Support:** Boehringer Ingelheim, Endoceutics, Palatin Technologies, QuatRx Pharmaceuticals, Shionogi Pharmaceuticals, TherapeuticsMD  **Consultant/Advisory Board:** AMAG Pharmaceuticals, Agile Therapeutics, Duchesnay Pharmaceuticals, ITF Pharma  **Commercial Interest Speakers Bureau:** AMAG Pharmaceuticals  **Salary and Stockholder:** Sermonix Pharmaceuticals |
| Donna Ryan, MD | **Consulting Fees:** Alyvent, Amgen, Bausch Health, Boeringer Ingelheim, Epitomee, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, Scientific Intake  **Commercial Interest Speakers Burea:** Novo Nordisk  **Contracted Research:** SELECT Steering Committee (Novo Nordisk)  **Ownership Interest:** Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health, Scientific Intake |
| Robert Schneider, MSW | No relationship reported |
| Andrea J. Singer, MD, FACP, CCD | **Consulting Fees:** AgNovos, Amgen, Eli Lilly, Radius, UCB  **Commercial Interest Speaker Bureau:** Amgen, Radius, TherapeuticsMD  **Contracted Research:** Radius Health, UCB |

**Acknowledgement of Commercial Support:**

This activity is supported by independent educational grants from AbbVie, AMAG Pharmaceuticals, Inc., Amarin, Duchesnay, Hologic, Merck, and Novo Nordisk.

**Learner Bill of Rights:**

Global Learning Collaborative and Omnia Education recognize that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill or performance. As part of Global Learning Collaborative and Omnia Education’s duty to you as a learner, you have the right to expect that your continuing medical education experience will include:

* Content that:
  + Promotes improvements or quality in healthcare;
  + Is valid, reliable, and accurate;
  + Offers balanced presentations that are free of commercial bias for or against a product/service;
  + Is vetted through a process that resolves any conflicts of interests of reviewers and faculty;
  + Is driven and based on learning needs, not commercial interests;
  + Addresses the stated objectives or purpose and;
  + Is evaluated for its effectiveness in meeting the identified educational need.
* A learning environment that:
  + Supports learners’ ability to meet their individual needs;
  + Respects and attends to any special needs of the learners;
  + Respects the diversity of groups of learners and;
  + Is free of promotional, commercial and/or sales activities.
* Disclosure of:
  + Relevant financial relationships reviewers, faculty and authors have with commercial interests related to the content of the activity and;
  + Commercial support (funding or in-kind resources) of the activity.